Proactive Investors - Run By Investors For Investors

Nemaura Medical targeting year-end for UK launch of its glucose monitor

Faz Chowdhury, chief executive of Nemaura Medical Inc (NASDAQ:NMRD), spoke to Proactive London's Andrew Scott to update on their European and FDA trials as work continues towards the launch in the UK of their non-invasive glucose monitor by the end of the year.

''We believe it'll be the world's first non-invasive glucose monitoring system''.

''It's a continuous monitor, you place it on the arm and it provides a read-out every five minutes''.

''It's a technology we've been developing over the last seven years or so ... we're in the process of awaiting CE approval in the UK and we're anticipating a soft launch in the UK by the end of the year''.

 
Meet Alliance Pharma PLC, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full NMRD profile View Profile

Nemaura Medical Inc Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use